PCOS and Pregnancy: Unveiling the Impact of AMH on Mothers and Their Babies
"Discover how Anti-Müllerian Hormone (AMH) levels in mothers with Polycystic Ovary Syndrome (PCOS) affect both maternal health and fetal development, offering new insights into managing PCOS during pregnancy."
Pregnancy is a delicate balancing act of hormones, where the conditions in the womb set the stage for a child's future health. For women with Polycystic Ovary Syndrome (PCOS), this hormonal environment is often disrupted, raising questions about its impact on both mother and developing baby. PCOS, characterized by high androgen levels, insulin resistance, and elevated Anti-Müllerian Hormone (AMH), can create unique challenges during pregnancy.
One hormone that has garnered attention is AMH. Typically known for its role in ovarian function, AMH is found in higher concentrations in women with PCOS. Recent research has begun to explore how these elevated AMH levels affect not only the mother but also the developing fetus. Understanding the dynamics of AMH during pregnancy in women with PCOS could unlock new strategies for managing the condition and improving outcomes for both mother and child.
This article dives into the latest findings on AMH in pregnant women with PCOS and its potential effects on their babies. We'll explore how AMH levels differ between mothers with and without PCOS, how these levels relate to other key hormones like testosterone and FSH, and what this means for the development of the fetus. By understanding these complex relationships, we can gain valuable insights into optimizing care for pregnant women with PCOS.
PCOS Pregnancy Risks and AMH
A 2026 statistics source reports that PCOS is associated with about two to four times higher odds of gestational diabetes, as well as higher rates of miscarriage and preeclampsia; it also identifies elevated AMH and increased CRP among the hormone and inflammation factors discussed. The available source excerpts do not provide a pooled figure for pregnancy outcomes by AMH level, though a 2026 Frontiers article describes a forest-plot comparison of clinical pregnancy rates for low versus high AMH among patients with PCOS. A separate 2026 article presents itself as a fact-checked PCOS pregnancy statistics report but its supplied excerpt gives no specific statistics.
AMH Research Across PCOS and Pregnancy
A longitudinal study asks how total and cleaved AMH, as well as androgens, change before and throughout pregnancy in women with and without PCOS. Its reported results say both AMH forms were significantly higher in women with PCOS than in controls from pre-conception through the third trimester (all P < 0.001). Another study was conducted to address discrepancies in the literature about using serum AMH as a diagnostic marker for PCOS. These studies reflect both investigation of AMH across pregnancy and debate over its diagnostic role.
AMH Levels: What the Research Reveals
A recent study investigated AMH levels in pregnant women with and without PCOS, as well as in their newborns via umbilical cord blood. The goal was to understand if and how PCOS affects AMH levels in both the mother and the developing fetus. Researchers measured AMH, testosterone, estradiol, and FSH levels in maternal blood, as well as in the umbilical artery and vein of the newborns. The study included 57 pregnant patients, some diagnosed with PCOS and others without the condition.
- Elevated AMH in Mothers with PCOS: Women with PCOS had significantly higher AMH levels in their blood compared to those without PCOS.
- Elevated AMH in Fetuses of Mothers with PCOS: Newborns of mothers with PCOS also had higher AMH levels in their umbilical cord blood, regardless of whether they were male or female.
- Testosterone Differences: Mothers with PCOS had higher testosterone levels, but there was no significant difference in testosterone levels in the fetuses based on the mother's PCOS status.
- FSH Levels: Interestingly, FSH levels were lower in mothers with PCOS who were carrying male fetuses, but not in those carrying female fetuses.
AMH, Pregnancy Outcomes, and Metabolic Context
A 2022 review reports that altered AMH levels are associated with increased miscarriage risk and lower live-birth rates among women with PCOS undergoing assisted reproductive technology; it also lists associations with preterm delivery, milder Müllerian anomalies, and PCOS features in adulthood. A 2025 study of cord blood reports that AMH levels were significantly higher in pregnancies complicated by type 2 diabetes than in gestational-diabetes or control pregnancies (P < 0.01 and P < 0.005, respectively). Separately, a 2024 review describes PCOS as involving higher prevalence of infertility, pregnancy complications, and cardiometabolic disorders, including obesity, insulin resistance, and type 2 diabetes. These findings concern different populations and outcomes, so they do not establish one shared AMH effect across all pregnancies.
Limits of AMH as a Diagnostic Criterion
A 2025 review describes AMH as a promising PCOS diagnostic biomarker because it correlates strongly with follicular count and tends to be elevated in women with PCOS, while also critically examining limitations of adding it to diagnostic criteria. A 2024 meta-analysis investigated including AMH levels in PCOS diagnostic criteria as part of the 2023 international evidence-based guideline. Another 2024 commentary raises the unresolved question of whether elevated AMH in PCOS should cause concern during pregnancy, referring to data from the Pregnancy in Polycystic Ovary study. Together, the supplied sources frame AMH's diagnostic and pregnancy significance as matters requiring careful interpretation rather than providing a single settled threshold or conclusion.
Implications and Future Directions
This research sheds light on the intricate hormonal environment of pregnancies affected by PCOS. The elevated AMH levels in both mothers and their fetuses suggest a potential link between maternal PCOS and fetal development. While the exact mechanisms are still being investigated, these findings open new avenues for understanding and potentially mitigating the long-term effects of PCOS on offspring.
AMH Within a Heterogeneous Condition
A 2020 review describes PCOS as a heterogeneous condition whose exact pathophysiological mechanisms remain unknown. It reports significantly increased serum AMH in PCOS and notes altered transcriptional regulation of AMH and its receptor, AMHR2. The article framing this topic also describes PCOS as involving high androgen levels, insulin resistance, and elevated AMH, raising questions about effects on the mother and developing baby. The supplied excerpts establish this as a complex research context but do not specify a particular causal effect of AMH on babies.
One key question is how these elevated AMH levels in fetuses might influence their future health. Some researchers theorize that increased AMH could affect the development of the reproductive system, potentially contributing to the development of PCOS-like traits in female offspring. Further research is needed to explore these possibilities and to determine the long-term consequences of prenatal AMH exposure.
Ultimately, this research emphasizes the importance of careful monitoring and management of pregnant women with PCOS. By understanding the hormonal dynamics at play, healthcare professionals can work to optimize the health of both mother and child, potentially reducing the risk of adverse outcomes and promoting long-term well-being.